focus -WSS

focus

author：Wikipedia 2025-09-30 00:36:07 - browse：12919

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
Next article： Resistance to opioid

entertainment

WSS

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

Latigo launches with $135 million for Vertex

15 die by electrocution after transformer explodes in northern India

Flagship, Pfizer team up in deal worth up to $7 billion

Study gives hint on South Asians’ higher risk of cardiovascular disease

Study gives hint on South Asians’ higher risk of cardiovascular disease

focus

focus

hotspot

Jerome Adams on the need for new antivirals for Covid

Here’s what’s in the FDA plan to include pregnant women in clinical trials

In age of alternative facts, a scholarly course on calling out crap

ACIP vaccine advisory panel sees its vacancies filled

Apple is now the first public company to be valued at $3 trillion

Twill hunts for pharma partner to market its depression app

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Johnson & Johnson sues to stop Medicare negotiation

Cancer drug shortages should be causing more outrage

US soldier in North Korean custody after crossing DMZ line

knowledge

Manchin plays down potential 3rd

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Lack of darker skin in textbooks, journals harms patients of color

ACIP vaccine advisory panel sees its vacancies filled

Readout Newsletter: Amylyx, Aurinia, and IQVIA

leisure time

entertainment

Wikipedia

Wikipedia